These reports may support a good safety profile of APT-β1-OMe-P because the aptamer has high specificity to TGF-β1, limited antigenicity, and irrelevance to antibody-dependent cellular cytotoxicity; therefore, APT-β1-OMe-P may be a promising agent for combination cancer therapy with few side effects. The gene discussed is TGFB1; the disease is cancer.